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ABSTRACT: Androgenetic alopecia (AGA) is a genetically determined progressive hair-loss condition
which represents the most common cause of hair loss in men. The use of the medical term
androgenetic alopecia reflects current knowledge about the important role of androgens and genetic
factors in its etiology. In addition to androgen-dependent changes in the hair cycle, sustained
microscopic follicular inflammation contributes to its onset. Furthermore, Prostaglandins have been
demonstrated to have the ability in modulating hair follicle cycle; in particular, PGD2 inhibits hair
growth while PGE2/F2a promote growth. Due to the progressive nature of AGA, the treatment should
be started early and continued indefinitely, since the benefit will not be maintained upon ceasing
therapy. To date, only two therapeutic agents have been approved by the Food and Drug
Administration and European Medicines Agency for the treatment of AGA: topical minoxidil and oral
finasteride. Considering the many pathogenetic mechanisms involved in AGA, various treatment
options are available: topical and systemic drugs may be used and the choice depends on various
factors including grading of AGA, patients’ pathological conditions, practicability, costs and risks. So,
the treatment for AGA should be based on personalized therapy and targeted at the different
pathophysiological aspects of AGA.
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Introduction
Androgenetic alopecia (AGA) is a genetically
determined progressive hair-loss condition
which represents the most common cause of
hair loss in men. The incidence and severity is
more common in Caucasian men than other
nationalities (1). It is estimated that prevalence
rates in Caucasian populations is around 12%
among men aged 18–29 years and approximately
50% among men aged 40–49 years; by the age of
80, over 90% of Caucasian men are affected to a
various degree (2). AGA is characterized by pro-
gressive miniaturization of the hair follicle,
resulting from alteration in the hair cycle; in fact
the duration of the anagen phase gradually
decreases, whilst the length of telogen remains
constant or is prolonged. This results in a
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reduction of hair in anagen and a relative
increase in numbers of follicles in telogen (3).
There is also a progressive miniaturization of the
entire follicular apparatus, leading to gradual
conversion of terminal hairs into vellus hairs
with a progressive reduction in hair density. The
pattern of loss follows the scale developed by
Hamilton (2), and later extended by Norwood (4)
which defines seven distinct categories. Three
areas of the scalp are affected preferentially: the
temples, vertex and mid frontal scalp, whereas
the occipital region is spared. This typical pat-
tern is due to the fact that hair follicles in the
frontal and vertex regions are androgen-sensitive
thanks to the elevated expression of androgen
receptors (ARs), whereas the occipital and tem-
poral regions contain androgen-insensitive hair
follicles (5).
The use of the medical term androgenetic alo-
pecia reflects current knowledge about the
important role of androgens and genetic factors
in AGA etiology. It has long been known that the
presence of testosterone in hair follicles is a pre-
requisite for AGA (6), while genetic factors mod-
ify the magnitude of the hair follicle response to
circulating androgens (7). In consideration of the
wide range of expressed phenotypes in AGA, a
polygenic mode of inheritance is established.
Gene association studies highlighted that the AR
gene variants are the primary culprit responsible
for AGA development. The ARs determines the
sensitivity of hair follicle to androgens and poly-
morphism of the AR gene is associated with
AGA; the Stu 1 polymorphism has the most sig-
nificant association (8). Several other genes that
could be associated include 5a reductase, aroma-
tase, estrogen receptor a and IGF-2 genes (9).
The role of androgen in AGA is well estab-
lished (1). The circulating testosterone is con-
verted by 5a-reductase enzyme into 5a-
dihydrotestosterone (DHT), which has tenfold
higher affinity to AR compared to testosterone.
The predisposed scalp exhibits high levels of
DHT with an increased expression of the ARs
(10). The cross-talk between the dermal papillae
and the hair follicle cells unfolded under the
influence of androgens results from the secretion
of many factors from the dermal papillae which
causes premature termination of anagen and
premature entry into catagen. Catagen occurs as
a consequence of decreased expression of ana-
gen maintaining factors, such as the growth fac-
tors IGF-1, bFGF and VEGF (11). Furthermore,
an increased expression of cytokines, such as
TGFb 1, IL 21a and TNF a promotes apoptosis.
In addition to androgen-dependent changes
in the hair cycle, sustained microscopic follicular
inflammation is considered a co-factor in the eti-
ology of AGA. A modest degree of chronic
inflammation around the upper part of hair fol-
licles has been described by many investigators
(12). The observation of activated T-cells infil-
trating about the lower portions of follicular
infundibulum suggests that the primary causal
event for the triggering of inflammation might
occur near the infundibulum (13). Micro inflam-
mation may be triggered by resident microbial
flora in the case of seborrhea, toxins and oxida-
tive stress; other factors include the aging pro-
cess, smoking, UV, and environmental pollutants.
These stressful influences lead to the formation
of free radicals which damage the hair follicles.
An outline is emerging for a fundamental role
of prostaglandins (PGs) in modulating hair fol-
licle cycle; in particular, PGs D2, E2, and F2a
have the ability to regulate hair growth. Clinical
data have demonstrated that PGD2 inhibits hair
growth while PGE2/F2a promote growth (14,15).
Recent studies suggested that PGD2 level is ele-
vated in male balding scalp (14), whereas PGE2
has been shown to be reduced.
PGD2 is synthesized by prostaglandin D2 syn-
thase (PTGDS), an enzyme hormone responsive
expressed in the outer root sheath inferior to the
bulge. PGD2 has two known receptors, GPR44
and PTGDR (16). GPR44 was found to be neces-
sary for the decrease in hair growth by PGD2; its
binding to the GPR44 receptor expressed in the
hair follicle seemed to induce miniaturization of
the follicle, thus probably, preventing the matu-
ration of stem cells into progenitor cells and of
vellus-like hair into terminal hair. This knowl-
edges could be important for the creation of new
target therapies for AGA, which inhibit the activ-
ity of PTGDS, PGD2 or GPR44 (16).
Thus the exact pathogenetic mechanism
underling AGA is not well elucidated, further
studies are needed to better understand it.
Management
Although AGA is a paraphysiological phenom-
enon, it causes significant changes in the out-
ward appearance of the patients and,
consequently, deep social implications particu-
larly in younger men (1). Due to the progressive
nature of AGA, treatments should be early
started and indefinitely continued, since the
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benefit will not be maintained upon ceasing
therapy.
Considering the many pathogenic mecha-
nisms involved in the onset of AGA, a various
treatment options are available. Topical and sys-
temic drugs, individually or combined, may be
used and the choice depends on various factors
including grading of AGA, efficacy, practicability,
costs and risks (17).
To date only two therapeutic agents have been
approved by the Food and Drug Administration
(FDA) and European Medicines Agency (EMA)
for treatment of AGA: topical minoxidil and oral
finasteride (1 mg/day) (5).
Medical management
Minoxidil
Minoxidil solution is the most frequently used
drug for topical application (18)] and it is
strongly recommended as a first-line topical
treatment for men with mild or moderate AGA
(19).
The mechanism by which minoxidil promotes
hair growth is still not completely understood. It
is converted to minoxidil sulphate, an active
metabolite which opens ATP-sensitive potassium
channels localized on the smooth muscular cells
of the peripheral artery, leading to a vasodilatory
effect. It is been observed that minoxidil is able
to increase the m-RNA expression for the VEGF
in the dermal papilla, inducing angiogenesis
(20). It has been shown that minoxidil stimulated
PGE2 and leukotriene B4 in vitro production by
dermal papilla cells, whereas inhibited prostacy-
clin synthesis. In addition, it increases the
expression of one of the four PGE2 receptors
called EP2 which may contribute to anagen pro-
longation. Minoxidil promotes also the survival
of dermal papilla cells by increasing Bcl-2/Bax
ratio and by activating ERK and Akt. It was
postulated that minoxidil would have anti-
fibrotic properties by inhibiting activity of the
enzyme lysyl hydroxylase in human skin fibro-
blast leading to synthesis of a collagen deficient
in hydroxylysine (21).
Progressively, thanks to minoxidil, the minia-
turized hair follicle stay longer in the anagen
phase, producing hair similar to the terminal
hair and decreasing shedding (21).
In approximately 50% men using minoxidil
solution, the hair loss process is arrested by
minoxidil; in addition, a small percentage of
men experiences mild to moderate degrees of
hair regrowth. However, after discontinuing the
therapy hairs fall out again (18).
Minoxidil solution contains ethanol, water,
and propylene glycol as vehicle. It is available in
2% and 5% solutions; the 5% minoxidil has
shown higher efficacy than the 2% solution (22).
Minoxidil have to be applied twice a day with
the dosage of 1 mL; 4–6 months of treatment are
needed to see significant results and the maxi-
mal effect is reached after approximately 1 year.
Patients answer better to treatment if hair minia-
turization is not advanced (Hamilton< IV) (18).
The safety profile of topical minoxidil solution
is favorable and its most common side effects
are scalp pruritus and scaling due to irritant and
allergic contact dermatitis. The 5% minoxidil for-
mulation, which contains more propylene glycol
was usually associated with a higher number of
cases of itching, erythema, and dryness (1). A
common side effect due to the action of Minoxi-
dil is telogen effluvium, caused by the encour-
agement of hairs already in the telogen phase to
shed early (17). The use of topical minoxidil can
also induce hypertrichosis in different areas out
of the scalp because of local/systemic absorption
or possible contamination of them (22). Patient’s
compliance is thought to be the major limiting
factor (23).
Minoxidil could be associated with other
active principles, separately administred or using
a galenic lotion. Combinations containing
minoxidil-pyrithione zinc and minoxidil-
hydrocortisone have been shown to improve hair
growth compared with the use of minoxidil
alone.
Finasteride
Finasteride, a synthetic 4-aza-3-oxosteroid com-
pound with poor aqueous solubility, is a highly
selective inhibitor of type II 5 alpha reductase.
Binding irreversibly to the enzyme, it inhibits the
conversion of testosterone to DHT decreasing
serum and cutaneous DHT concentrations (24).
The underlying principle for its use in the treat-
ment of AGA is the reduction of DHT production
and the inhibition of androgen-dependent mini-
aturization of hair follicles. The clinical effective-
ness and safety of finasteride has been evaluated
in a well controlled clinical trials which moni-
tored 1.879 men with AGA, demonstrating that
treatment with oral finasteride 1mg/d for 5 years
resulted in hair loss reduction. In order to evalu-
ate the long term efficacy and safety of oral
finasteride 1mg/d, we enrolled 118 men aged
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between 20 and 61 years affected by AGA and
monitored for a 10 years period. The results
underlined that finasteride 1 mg/d administra-
tion produced significant and durable increases
in hair growth (25). Of the 113 patients followed
for 10 years, only 14% worsened, while the
remaining had benefits (21%) from the treatment
duration or persisted in their improvements
(65%). In our opinion, the result after the first
year can help in predicting the effectiveness of
the treatment. In fact, the majority of patients
that do not show any improvement within the
first year of treatment could be considered not
respondent to a long-term therapy (25).
Finasteride 1 mg/d is generally well tolerated;
the reported sexual side effects are few and not
age related (26) and appear to resolve on cessation
of the drug (26,27). The increased estrogen levels,
caused by partial conversion of testosterone in
estradiol through the aromatase enzyme, can lead
to problems like water retention, adiposity, gyne-
comastia and increased risk of breast cancer, while
low levels of DHT can lead to sexual dysfunctions,
such as loss of libido, erective dysfunction and
reduction in amount of ejaculated semen (26).
According to a very large prospective study, the
effect of finasteride on sexual functioning is mini-
mal for most men but may worsen the patient’s
quality of life or even reduce compliance to treat-
ment. The satisfactory clinical results and the few
side effects observed, led to consider finasteride
an effective treatment (25).
The FDA has approved the use of finasteride
in oral formulations, but considering that the
oral administration has led to undesirable sys-
temic side effects and that 5a-reductase is
mainly located in the hair follicle, the use of a
percutaneous approach was investigated by sev-
eral authors (27,28).
A study that evaluated a finasteride 0.25% top-
ical solution in comparison to the oral finaster-
ide 1 mg/d, found a strong and similar
inhibition of plasma DHT after 1 week of treat-
ment with the topical and tablet finasteride for-
mulations, while finasteride plasma exposure
was significantly lower with the topical than with
the oral formulation (28).
A double blind, randomized clinical trial of 45
male baldness patients that compared the thera-
peutic effects of finasteride gel 1% and the oral
finasteride 1 mg/d after 6 months of treatment
proved with serial measurement a significant
increase in terminal hair counts in both groups
and showed no significant statistical differences
between two groups (29). Preliminary results of
our study evaluating the efficacy of finasteride
0.5% topical solution in treatment of AGA have
shown that the application of a 1 mL/d induced
a clinical improvement in absence of side effects.
The results of these studies demonstrated that
topical finasteride represents a good replacement
of oral therapy, especially in patients who worry
about its side effects. However, further studies
are needed to confirm its efficacy and the long
term side effects.
Other 5-alpha-reductase inhibitors
Dutasteride, a dual inhibitor of both type I and
type II 5 alpha-reductase, has recently been
tested to improved efficacy over finasteride in
promoting hair growth (30). Type II 5a-reductase
is the predominant 5a-reductase enzyme
expressed in scalp, while type I 5a-reductase is
principally expressed in scalp sebaceous glands.
Dutasteride is approximately 3 times more
potent than finasteride at inhibiting type II 5
alpha reductase and 100 times more potent at
inhibiting of the type I. A multicenter, prospec-
tive study in which 110 Japanese male patients
with AGA took dutasteride at the dose of
0.50.5 mg/d for 52 weeks, determined long-term
safety, tolerability and efficacy of dutasteride
within this study population (31). So, dustaster-
ide could be considered as a potential treatment
option for AGA; furthermore, for its effects on
sebaceous glands, it could be useful also in the
treatment of patients with AGA associated with
seborreic dermatitis.
As in alternative to oral finasteride, Serenoa
repens could be considered an approach in
treating low or moderate AGA (19). Serenoa
repens is a plant of the Arecaceae’s family and
its berries are highly enriched with fatty acids,
phytosterols and flavonoid which have anti-
androgenic activity through the competitive and
nonselective inhibition of 5-alpha reductase type
I and II (32,33). Inhibiting 5aR, it decreases DHT
uptake by hair follicle and the binding of DHT to
ARs. Furthermore, Serenoa activates the estro-
gens receptor contributing to the anagen mainte-
nance and to the catagen normalization. In
literature there are few articles that underline the
effectiveness of Serenoa in treating AGA. In a
small study of 10 males with AGA taking oral
Serenoa, improvement was seen in 60% (32). In
our study (33), we compared the therapeutic
effect of Serenoa with finasteride. We enrolled
100 patients with mild and moderate AGA; one
group received Serenoa 320 mg every day for 24
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months while the other received finasteride 1 mg
for the same period. The results showed that
patients with an increase in hair growth are 38% in
the group treated with Serenoa and 68% in the
second group. We also observed that Serenoa acts
prevalently in the vertex, while finasteride acts in
both the front area and the vertex (33). The most
common side effects is mild stomach discomfort
which can be alleviated by taking it after food. So,
with the recommended dose of 320 mg/day,
Serenoa, for its uncommon side effects is consid-
ered a non invasive approach to AGA.
Other treatments
Considering the multifactorial etiology of AGA,
besides the treatment with minoxidil and finas-
teride and, more successfully, hair transplanta-
tion, other active principles were investigated.
Topical antiandrogen
Knowledge of the important role of androgen in
genetically predisposed individuals leads to the
idea that the use of AR blockers may be useful in
the treatment of AGA (7). However, systemic
anti-androgen treatments cannot be used in
men due to its feminization effects, such as
gynecomastia, feminization and impotence. For
this reason it is necessary to use AR blockers
that block AR selectively in scalp hair follicles.
Recently, fluridil, a topical antiandrogen similar
in structure to flutamide has been developed for
use in AGA (1). It suppresses ARs in hair follicles
and degrades into inactive metabolites without
systemic anti-androgenic effects. A double-blind,
placebo-controlled study showed that patients
using topical fluridil had an increase in the ana-
gen to telogen ratio, and the maximum attain-
able effect was achieved within the first 90 days
of daily use. Sexual function, libido, hematology
and blood chemistry values were normal over
the duration of the investigation (1). Neverthe-
less a long term study is required to further
investigate fluridil’s long-term safety and effec-
tiveness in AGA.
Topical ketoconazole
There is some evidence that ketoconazole, an
imidazole broad-spectrum antifungal and steroid
biosynthesis inhibitor, when used topically could
stimulate hair growth. The mechanism is
unknown, but may involve reducing inflamma-
tion through its anti-inflammatory effects against
T cells and through its activity against microflora
of the skin by Malassezia (34). It also has anti-
androgenic properties through DHT pathway
disruption.
So, Ketoconazole shampoo, for its anti-
infiammatory and anti-androgenic properties, is
a good additive treatment and could be useful in
case of associated seborrheic dermatitis.
However, clinical trials are needed to evaluate
the effectiveness of ketoconazole in the treat-
ment of AGA (1).
Prostaglandin F2a analogues
Prostaglandins (PGs) have already been shown to
be important in hair follicle function (14,16).
Consequently, PGs dysregulation may contribute
to AGA pathogenesis, offering potential thera-
peutic targets for its treatment. Bimatoprost and
latanoprost, two analogues of PG F2a used to
decrease ocular pressure in glaucoma, were inci-
dentally noted to cause hair lengthening (15).
This clinical observation led to the FDA approval
of the use of bimatoprost 0.03% solution for
hypotrichosis of the eyelashes (35). The discov-
ery of the potency for latanoprost and bimato-
prost to induce hair lengthening remains some
of the strongest evidence to implicate PGs in
hair follicle function. The PG analogues stimu-
late hair growth supposedly by prolonging the
anagen phase of the hair cycle (35). As previously
mentioned, one proposed action of minoxidil
that may be relevant to hair regrowth is stimula-
tion of PG synthesis (21). So, it would seem sen-
sible to consider the direct application of a PG
analogue to the hair follicle, rather than to indi-
rectly stimulate PG synthesis with minoxidil (14).
However, further studies are needed to confirm
its long term efficacy and side effects.
Nigella sativa
Nigella sativa (NS) is an annual flowering plant
native to Mediterranean countries, Pakistan and
India with a wide spectrum of pharmacological
actions. NS seeds and its oil extract have been
demonstrated to have anti-tumoral, anti-oxidant
and anti- inflammatory activities (36). Thymo-
quinone, which represents the predominant
component (30–48%), showed anti-inflammatory
effects for its ability to suppress pro-
inflammatory cytokines such as IL-1b, TNF-a,
IL-4, IL-5, IL-3; furthermore it inhibits COX-2
expression, PGD2 synthesis and NF-kB activa-
tion, contributing to the regulation of hair cycle
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(36). Regarding this, we could consider the use
of NS as a possible treatment for AGA. Our
double-blind, placebo controlled and random-
ized study in which ten patients affected by telo-
gen effluvium were treated with 2 mL of topic
formulation containing 0.5% NS essential oil, 3%
glycerin, 0.4% lavender essential oil and 60%
alcohol to 100 mL every day for 3 months, dem-
onstrated NS efficacy by an improvement of hair
density and hair thickness after 3 months of
treatment and a reduction of inflammation
observed in the majority of patients (37).
However clinical trials are needed to evaluate
the effectiveness of Nigella sativa in the treat-
ment of AGA.
Growth factors
The growth and development of hair follicles is
influenced by a number of different growth fac-
tors and cytokines. In this view, platelet rich
plasma (PRP) isolated from whole blood can be
used for its growth factors and stimulatory medi-
ators. PRP is defined as an autologous concen-
tration of platelets (usually more than 1,000,000
platelets/lL) in concentrated plasma (38); it is
produced using different methods for platelet
concentration through centrifugation and cell
separation, and then, it is injected in the
androgen-related areas of scalp. PRP is known to
carry more than 20 GFs and other protein mole-
cules, such as adhesion molecules, chemokines,
which interact to promote angiogenesis, extracel-
lular matrix remodeling, cell proliferation and
differentiation (39). Main GFs stored in a-
granules of platelets are platelet- derived growth
factor (PDGF), transforming growth factor-b
(TGF-b) and vascular endothelial growth factor
(VEGF) with their isoforms; PDGF and VEGF
appear to be important mediators of hair follicle
growth by increasing the perifollicular vascular
plexus. GFs appear to act in the bulge area of
the follicle, in which they bind to their respective
receptors located in primitive stem cells of ecto-
dermal origin, giving origin to epidermal cells
and sebaceous glands (39). Furthermore, acti-
vated PRP seems to promote differentiation of
stem cells into hair follicle cells through the
upregulation of b-catenin, strongly expressed in
the bulge region, and to prolong anagen phase
through increased expression of fibroblast
growth factor-7. A clinical study conducted by V.
Cervelli et al suggested that the injection of PRP
preparations has a positive therapeutic effect on
hair loss without major side effects (40). In our
experience, PRP associated with medical therapy
allows to obtain clinical response in less time
than the medical therapy alone. So, PRP avail-
able alone or in association with conventional
drugs for AGA could constitute a useful tool for
AGA treatment, however few trials in its support
have been published. More randomized, con-
trolled, double-blind studies with larger sample
size, long follow-up and objective evaluation
methods are needed.
Laser treatments
Paradoxical hair growth after using lasers for hair
removal has triggered interest in using these
devices in the treatment of AGA (24). In recent
years, low-level laser therapy (LLLT), has been
promoted to stimulate hair growth in patients
with AGA. There is evidence that laser light can
stimulate hair growth at some wavelengths, how-
ever the biological mechanism has not been
defined (1). Light of 650–900 nm wavelengths at
5 mW has been suggested as an effective option
for AGA (41). Leavitt et al. reported that the
treatment with HairMax LaserComb was effective
in increasing terminal hair density after 26 weeks
of treatment; treatment group showed a signifi-
cantly greater increase in mean terminal hair
density than subjects in the sham device group
(41). Though there has been only one published
study supporting the efficacy, the device has
since been approved for treating AGA. In addic-
tion, Kim et al. reported that after 24 weeks of
treatment, a low-level light therapy group
showed significantly greater hair density than
the sham device group (42). A statistically signifi-
cant positive trend in hair growth was also
observed from a multicenter, randomized, d
ouble-blind study that evalueted the efficacy of
the novel cold X5 hairlaser device for treating
AGA (43). Further clinical trials are needed to
define the efficacy of laser treatments.
Potential future treatments
Cetirizina
It is been demonstrated that PGD2 functionally
inhibits hair growth through its binding to the
GPR44 receptor expressed in the hair follicle and
it is elevated in male balding scalp (14); so, its
inhibition could be considered as a target ther-
apy in AGA. Cetirizine is a H1 antihistamine and
was first described as a specific anti-H1 mole-
cule displaying potent anti allergic activity.
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However, the action of cetirizine does not apply
only at the level of H1 receptors. A study of
Charlesworth et al., investigating the effects of
cetirizine on mast cell-mediator release and cel-
lular traffic during the cutaneous late-phase
reaction, showed that the production of PGD2
was clearly reduced by cetirizine treatment (44).
A study of Roch-Arveiller et al., investigating the
effect exerted by various concentrations of cetiri-
zine (0.1–10 micrograms/mL) applied in vitro to
human monocytes, showed that cetirizine
enhanced PGE2 release by human monocytes
(45).Considering the action of cetirizine in inhib-
iting the release of PGD2 and in stimulating of
the release of PGE2, we evaluated the efficacy of
galenic solution containing cetirizine 1% in the
treatment of mild and moderate AGA. Our clini-
cal experience has shown that the application of
a 1 mL/d of cetirizine topical 1% induced a clini-
cal improvement in absence of side effects. So,
cetirizine could be considered in alternative to
conventional treatment of AGA, especially in
case of inflammation of the scalp. However, fur-
ther research and clinical trials are required to
determine its long term efficacy and side effects.
Adipose derived stem cells
Recent research suggested an interplay between
hair follicle cells and adipocytes, showing the
potential roles of intradermal adipocytes in hair
follicle thanks to their regulatory properties dur-
ing hair follicle cycling; recently, adipocytes were
overlooked as niche cells that produce growth
signals (46). In fact, intradermal adipocytes are
recognized for more than just their roles in
energy storage, thanks to their secretion of hor-
mones, growth factors and cytokines, such as
leptin, PDGF and tumor necrosis factor-alpha, as
well as proteins related to immunological and
vascular functions. Festa et al. (47), using histo-
logical and functional analysis of cell popula-
tions of the adipocyte lineage, analyzed the role
of intradermal adipocytes on follicular stem cells
activity. In this study they identified a dynamic
process of adipogenesis that parallels the activa-
tion of hair follicle stem cells and revealed that
immature adipocyte cells are necessary and suf-
ficient to activate follicular stem cells. In particu-
lar, they focused on PDGFa secreted by
adipocyte precursor cells as the factor to pro-
mote hair growth. In this view, we decided to
treat patients with AGA for 6 months with appli-
cation of adipose-derived stem cells (ADSCs)
through the injection of adipose tissue lipoaspi-
rates obtained from the abdomen and hip
regions of donors using a cannula with small
holes at a very superficial level of adipose tissue
that allows a greater yield of adipose-derived
stem cells (48). After 6 months, serial measure-
ments indicated a significant increase in hair
counts, without side effects. However, clinical tri-
als are required to evaluate its long term efficacy
and side effects.
Surgical management
In severe AGA, management option is hair trans-
plantation surgery (18) which involves removal
of hair follicles from the occipital scalp, which is
relatively androgen resistant, and their reimplan-
tation into the bald vertex and frontal scalp (4).
Prerequisite for the procedure is sufficient hair
on the occipital scalp; a scalp density of 100 fol-
licular U/cm2 is considered excellent (4). Follicu-
lar unit transplant (FUT) is considered the gold
standard because it preserves the natural archi-
tecture of the hair units and gives natural results.
Grafts for FUT may be obtained through the strip
harvesting method or Follicular Unit Extraction
(FUE) harvesting. In the strip harvest method, a
strip of scalp is excised from the occipital scalp
and the wound is sutured; the donor strip is
then dissected under a microscope into the fol-
licular units (FUTs) and then transplanted into
the balding area (1).
In FUE harvesting, individual FUTs are
extracted directly from the donor site with 1 mm
punch biopsy and then, using a micro blade,
each unit is reinserted back into the bald areas.
Compared with the traditional strip harvest tech-
nique, FUE tends to be more costly and takes
more time (48). More recently, automated FUE
systems have been developed to reduce the pro-
cedure time and transection rate.
Surgical results can be adequately assessed
after no less than 3 months because the trans-
planted follicle will take up to 3 months to reach
the anagen phase and become noticeable and, in
addition, transplanted hairs seem to immediately
go into a telogen phase after insertion. There is
always a degree of graft failure, depending on
the skill of the surgeon, the density of graft
placement, preparation of the graft units and
their desiccation (1).
In patients in which the transplant is per-
formed with the aim to increase the density of
hairs in the front area or vertex, topical minoxidil
and finasteride can be a useful adjunct therapy
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following hair transplantation in order to prevent
non-transplanted hairs loss and in order to
achieve their growth. Because of a different
mechanism of action for each drug and the syn-
ergic effect when combined, it is recommended
using both finasteride and minoxidil (4). The use
of minoxidil in perioperative period has the
advantage of stabilizing the hair loss, increasing
the number of hair in anagen phase and
decreasing post surgical telogen effluvium (49).
Minoxidil should be stopped 2 to 3 days before
surgery to reduce the risk of intraoperative
bleeding caused by vasodilation; treatment
should be restarted in 1–2 weeks (21). Random-
ized, double-blind trial using finasteride 1 mg
daily or placebo in 79 men with AGA 4 weeks
before and 48 weeks after hair transplantation
demonstrated that the treatment group had sig-
nificant improvement from baseline, in compari-
son with placebo group (50)]. Another useful tool
to support hair transplant surgery is the injection
(subcutaneous, intradermal, interfollicular) of
PRP in the scalp in order to encourage trans-
planted graft growth (39).
Conclusions
In conclusion, a better understanding of the
pathophysiology of AGA should lead to more suc-
cessful treatment based on multi-therapeutic
approach, targeted at different pathophysiological
aspects of AGA, such as excessive sensitivity of the
hair follicle to androgen, microinflammation and
PGs dysregulation. For this reason the treatment
of AGA should be based onmultiple drugs, consid-
ering also the pathological conditions associated,
such as the inflammatory conditions of the scalp
that are often encountered during medical exami-
nation and therapeutic expectations of patients.
In the next future, the understanding of the
molecular genetic etiology and patho-
physiological aspects of AGA will provide a path-
way to the development of more efficacious, per-
sonalized and targeted treatment options.
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